Research & Diagnostic Antibodies LLC (R&D Antibodies) announced today that it has received a notification stating that the European Patent Office intends to grant a patent for its monoclonal antibody-based immunoassays and apparatuses for measuring inducible nitric oxide synthase (iNOS) as a plasma biomarker for the early detection of the sepsis pathology.
This notification is equivalent to a “Notice of Allowance” by the United States Patent Office. European patent application 01959345 covers very broadly the use of R&D Antibodies’ immunoassays, kits, and apparatuses for the detection of plasma iNOS as a biomarker for the prognosis and diagnosis of Systemic Inflammatory Response Syndrome (SIRS) that will deteriorate into sepsis. This European Patent Office allowance of claims extends R&D Antibodies’ existing patent portfolio in this field (USA #6531578-B1 and 7198904-B1, European #EP1012605, Japan #4117911, and Australian #2001280912 and 782922). Equivalent patent applications are also pending in the USA, Japan, Australia and Canada.